CLINICAL TRIALS PROFILE FOR NEO-MEDROL

All Clinical Trials for Neo-medrol

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002524 ↗	Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	1993-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002524 ↗	Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma	Completed	M.D. Anderson Cancer Center	Phase 2	1993-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002831 ↗	Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	1995-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of high-dose chemotherapy plus peripheral stem cell transplantation in treating patients with chronic myelogenous or acute leukemia.
NCT00002831 ↗	Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia	Completed	M.D. Anderson Cancer Center	Phase 1/Phase 2	1995-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of high-dose chemotherapy plus peripheral stem cell transplantation in treating patients with chronic myelogenous or acute leukemia.
NCT00002833 ↗	Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia	Completed	National Cancer Institute (NCI)	Phase 2	1994-10-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus filgrastim in treating patients who have acute or chronic myelogenous leukemia.
NCT00002833 ↗	Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia	Completed	M.D. Anderson Cancer Center	Phase 2	1994-10-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus filgrastim in treating patients who have acute or chronic myelogenous leukemia.
NCT00002835 ↗	Combination Chemotherapy in Treating Patients With Lymphoma	Completed	National Cancer Institute (NCI)	Phase 3	1995-10-30	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy in treating patients who have intermediate-grade or immunoblastic lymphoma.

Clinical Trial Conditions for Neo-medrol

Condition Name

Condition Name for Neo-medrol
Intervention	Trials
Leukemia	15
Acute Lymphoblastic Leukemia	6
Graft Versus Host Disease	6
Osteoarthrosis	6

Condition MeSH

Condition MeSH for Neo-medrol
Intervention	Trials
Leukemia	22
Leukemia, Lymphoid	16
Precursor Cell Lymphoblastic Leukemia-Lymphoma	15
Syndrome	13

Clinical Trial Locations for Neo-medrol

Trials by Country

Trials by Country for Neo-medrol
Location	Trials
United States	420
Canada	42
China	16
Denmark	14
Australia	12

Trials by US State

Trials by US State for Neo-medrol
Location	Trials
Texas	30
California	21
Ohio	17
New York	16
Indiana	15

Clinical Trial Progress for Neo-medrol

Clinical Trial Phase

Clinical Trial Phase for Neo-medrol
Clinical Trial Phase	Trials
Phase 4	18
Phase 3	20
Phase 2/Phase 3	6

Clinical Trial Status

Clinical Trial Status for Neo-medrol
Clinical Trial Phase	Trials
Completed	57
Recruiting	18
Active, not recruiting	12

Clinical Trial Sponsors for Neo-medrol

Sponsor Name

Sponsor Name for Neo-medrol
Sponsor	Trials
National Cancer Institute (NCI)	20
M.D. Anderson Cancer Center	16
Bispebjerg Hospital	7

Sponsor Type

Sponsor Type for Neo-medrol
Sponsor	Trials
Other	130
Industry	39
NIH	32

NEO-MEDROL (Methylprednisolone): Clinical Trials, Market Analysis, and Projections

Overview of NEO-MEDROL (Methylprednisolone)

NEO-MEDROL, also known as Methylprednisolone, is a corticosteroid used to treat a variety of inflammatory and autoimmune conditions. It is widely recognized for its anti-inflammatory and immunosuppressive properties, making it a staple in the treatment of diseases such as dermatitis, eczema, and various musculoskeletal disorders.

Clinical Trials and Efficacy

Recent Clinical Trials

Clinical trials involving Methylprednisolone have been conducted to evaluate its efficacy in various clinical settings. For instance, a prospective study on rectal and anal cancer patients undergoing intersphincteric resection compared the effects of Methylprednisolone (Sou-Medrol) with celecoxib and a placebo on postoperative inflammation and cancer recurrence. The study found that while Methylprednisolone effectively reduced postoperative inflammation, it did not significantly impact the recurrence rate of rectal cancer compared to the other groups[5].

Challenges and Controversies

Highly cited clinical trials, including those involving Methylprednisolone, sometimes face challenges when subsequent larger or better-controlled studies contradict or modify their findings. For example, initial trials may show stronger effects that are later found to be less significant or even contradicted by larger studies. This phenomenon highlights the importance of ongoing research and the need for larger, more robust trials to confirm initial findings[1].

Market Analysis

Market Size and Growth

The Methylprednisolone market is projected to grow significantly over the next few years. By 2027, the market size is estimated to reach $917.4 million, growing at a Compound Annual Growth Rate (CAGR) of 3.4% from 2022 to 2027. This growth is driven by the increasing prevalence of autoimmune disorders and the rising geriatric population, which are key factors contributing to the demand for corticosteroids like Methylprednisolone[2].

Geographical Distribution

Geographically, North America held a dominant market share in 2021, primarily due to the robust healthcare infrastructure and the presence of major drug manufacturers. However, the Asia-Pacific region is expected to offer lucrative growth opportunities due to the rapid increase in the geriatric population and the rising awareness of better medical conditions and facilities[2].

Distribution Channels

The market is segmented into offline and online retail channels. Offline retail dominated the market in 2021, driven by the immediate need for treatments in emergency settings such as hospitals. However, the online segment is expected to grow at a CAGR of 4.0% over the forecast period, driven by strategies such as memberships, cashback, and discounts adopted by new market entrants[2].

Market Drivers

Growing Prevalence of Autoimmune Disorders

The increasing prevalence of autoimmune disorders, such as rheumatic diseases, is a significant driver of the Methylprednisolone market. Factors like old age, smoking, early-life exposure to smoking, and obesity contribute to the rise in these diseases, making Methylprednisolone a crucial treatment option[2].

Healthcare Expenditure and Government Incentives

Government incentives and increased healthcare expenditure, particularly in regions like North America and Asia-Pacific, also drive the market growth. For instance, India's healthcare expenditure increased by up to 137% in 2021, indicating a strong commitment to improving medical facilities and treatments[2].

Market Challenges

Side Effects and Alternatives

Despite the growth, the Methylprednisolone market faces challenges related to the side effects associated with long-term steroid use. These side effects can include a range of health issues, prompting the search for alternative treatments and potentially impacting market growth[2].

Projections and Future Outlook

Segment Growth

The rheumatic disorder segment is expected to be the fastest-growing, with a CAGR of 3.8% over the forecast period. This growth is attributed to the increasing prevalence of risk factors such as old age, smoking, and obesity[2].

Online Retail Growth

The online retail segment is projected to grow significantly, driven by innovative marketing strategies and discounts offered by new market entrants. This shift towards online retail is expected to continue, making it a key area of focus for market players[2].

Key Takeaways

• The Methylprednisolone market is expected to reach $917.4 million by 2027, growing at a CAGR of 3.4%.
• North America currently dominates the market, but the Asia-Pacific region is poised for significant growth.
• The growing prevalence of autoimmune disorders and the rising geriatric population are key market drivers.
• Online retail is expected to grow rapidly due to innovative marketing strategies.
• Side effects associated with long-term steroid use remain a challenge for the market.

FAQs

What is NEO-MEDROL (Methylprednisolone) used for?

NEO-MEDROL (Methylprednisolone) is used to treat various inflammatory and autoimmune conditions, including dermatitis, eczema, and musculoskeletal diseases.

What is the projected market size of Methylprednisolone by 2027?

The Methylprednisolone market is estimated to reach $917.4 million by 2027.

Which region is expected to offer the most growth opportunities for Methylprednisolone?

The Asia-Pacific region is expected to offer lucrative growth opportunities due to the rising geriatric population and increasing awareness of better medical conditions.

What are the main drivers of the Methylprednisolone market?

The main drivers include the growing prevalence of autoimmune disorders, rising geriatric population, and increased healthcare expenditure.

What challenges does the Methylprednisolone market face?

The market faces challenges related to the side effects associated with long-term steroid use and the potential for alternative treatments.

How is the online retail segment expected to grow in the Methylprednisolone market?

The online retail segment is expected to grow at a CAGR of 4.0% over the forecast period, driven by innovative marketing strategies and discounts offered by new market entrants.

Sources

1. Ioannidis, J. P. A. (2005). Contradicted and Initially Stronger Effects in Highly Cited Clinical Research. JAMA, 294(2), 218-228.
2. IndustryARC. Methylprednisolone Market - Forecast(2024 - 2030).
3. TN.gov. Performance Drug List.
4. Mordor Intelligence. Oncology Clinical Trials Market Size & Share Analysis - Growth Trends.
5. Synapse by Patsnap. Fradiomycin Sulfate/Methylprednisolone.